CreatorsPublishersAdvertisers

#Cell Therapy

drugdiscoverytrends.com

FDA backs stem cell therapy for COVID-19 under compassionate use program

The Global Institute of Stem Cell Therapy and Research (GIOSTAR) has announced that the FDA has authorized emergency use of its stem cell therapy for hospitalized COVID-19 patients. The San Diego–based organization has offered stem cell therapy for COVID-19-related symptoms since April 2020. The compassionate use authorization will enable GIOSTAR...
SAN DIEGO, CA
Picture for FDA backs stem cell therapy for COVID-19 under compassionate use program
denversun.com

The Beta-Thalassemia treatment market is expected to grow significantly due to the launch of emerging therapies during the forecast period (2021-30)

According to the National Organization for Rare Disorders, Beta-Thalassemia is a relatively rare autosomal recessive disorder in the United States, but it is one of the most common autosomal recessive disorders globally. The incidence of Beta-Thalassemia symptomatic cases in the general population is estimated to be 1 in every 100,000 people.
Picture for The Beta-Thalassemia treatment market is expected to grow significantly due to the launch of emerging therapies during the forecast period (2021-30)
cellandgene.com

Cell & Gene Therapies: A Roadmap To Solving 6 Challenges Over The Next Decades

This past year has seen remarkable progress in the growth of cell and gene therapies with the approval of new therapies, their adoption in the clinical space, and the growth of RNA therapeutics to address COVID-19. This progress will lead to a better understanding of the underlying physiology and pathology...
SCIENCE
Picture for Cell & Gene Therapies: A Roadmap To Solving 6 Challenges Over The Next Decades
TRENDING TOPICS
healio.com

Anatomical, functional improvements seen with OpRegen in phase 1/2a study

Interim results from a study investigating OpRegen suggest a single treatment may provide improvements in patients with dry age-related macular degeneration with geographic atrophy, according to a Lineage Cell Therapeutics press release. OpRegen, an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space,...
HEALTH
onclive.com

Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCL

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma. Alex Herrera, MD, a hematologist/oncologist, and an assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma (DLBCL).
HEALTH
murphyshockeylaw.net

Autologous Cell Therapy Market Insights 2021 : Industry Revenue with Leading key players (BioTime, Pharmicell, BrainStorm Cell Therapeutics and More)

Autologous Cell Therapy Market Insights 2021 : [98 Pages Report] Autologous cell therapy refers to the injection or delivery of human tissue or cells to the same person to treat pathological conditions. For the same purpose, the stem cells are taken out of the patient, harvested, cultured, and transplanted again to the same person. The purpose of this method is to reduce the chance of rejecting treatment in the body. In addition, autologous cell therapy does not require immunosuppression.
MedicalXpress

Researchers explore promising new stem cell treatment for MRSA superbug

A study released in STEM CELLS Translational Medicine (SCTM), by researchers at the Baker Institute for Animal Health, part of Cornell University's College of Veterinary Medicine, Ithaca, N.Y., details in a relevant ex vivo model how treating wounds with the secretion of a type of stem cell called mesenchymal stromal cell (MSC) effectively reduced methicillin-resistant Staphylococcus aureus – better known as MRSA viability and stimulated the surrounding skin cells to build up a defense against the bacterial invader.
SCIENCE
myvetcandy.com

'Stealthy' stem cells better for treating tendon injuries in horses

Treating equine donor stem cells with a growth factor called TGF-β2 may allow them to avoid "tripping" the immune response in recipients, according to new research from North Carolina State University. The work could simplify the stem cell treatment process for ligament and tendon injuries in horses, and may also have implications for human stem cell therapies.
ANIMALS
groundalerts.com

Musculoskeletal Disorder Stem Cell Therapy Market 2021 Report Forecast by Global Industry Trends, Future Growth, Regional Overview

MarketStudyReport.com adds New Report on Global Musculoskeletal Disorder Stem Cell Therapy Market to its research database. The report focuses on global major leading players with information such as company profiles, Growth, product segment, technology segment, end user segment and region. The latest research report on Musculoskeletal Disorder Stem Cell Therapy...
HEALTH
drugtargetreview.com

Cell & Gene Therapy Advancements Whitepaper

Considering the growing number of benefits that cell and gene therapies have provided when treating a wide range of conditions, researchers around the world have turned their attention to this next-generation class of biologics. From lower dosages to longer-lasting effects, the advantages of these therapies mean that scientists are working to accelerate them towards the clinic. In the original pieces listed below, experts in this whitepaper discuss the most recent progress in cell and gene therapies, from immuno-oncology to gene therapy for ocular conditions to stem cells.
targetedonc.com

Treatment Methods: Transplant Eligibility in R/R DLBCL and CAR T Cell Therapy

The experts delve further into treatment methods for relapsed/refractory diffuse large B-cell lymphoma, particular for transplant-eligible and -ineligible patients. Mazyar Shadman, MD, MPH: In the past 2 years, we’ve had access to a number of new treatment agents or modalities, and I just wonder what your standard practice is. We are waiting for some of the recently announced press releases from some head-to-head trials comparing standard of care to CAR [chimeric antigen receptor] T-cell therapy, but at the moment at least we don’t have any details of those studies. Our standard approach would be to use a second-line chemotherapy, a platinum-based therapy, to achieve a complete remission or maybe a good partial remission as we move with autologous stem cell transplant. There are, of course, patients who are not eligible for a stem cell transplant. I was wondering what your approach is in general in the relapse setting, and then also for patients who are not eligible for a transplant?
cancertherapyadvisor.com

Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

The following article features coverage from the 2021 Annual Meeting of the Society of Hematologic Oncology (SOHO). Click here to read more of Cancer Therapy Advisor’s conference coverage. A single dose of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, yielded early, deep, and...
YOU MAY ALSO LIKE